Effects of evolving lipid-lowering drugs on carbohydrate metabolism
| Autor: | Moses Elisaf, V. Tsimihodimos |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Endocrinology
Diabetes and Metabolism 030204 cardiovascular system & hematology Pharmacology Carbohydrate metabolism 03 medical and health sciences 0302 clinical medicine Endocrinology Risk Factors Diabetes mellitus Internal Medicine medicine Humans 030212 general & internal medicine PCSK9 Inhibitors Dyslipidemias business.industry Lipid metabolism General Medicine Carbohydrate medicine.disease Lipid Metabolism Carbohydrate Metabolism lipids (amino acids peptides and proteins) Lipid lowering Hydroxymethylglutaryl-CoA Reductase Inhibitors business Dyslipidemia Homeostasis |
| Zdroj: | Diabetes research and clinical practice. 137 |
| ISSN: | 1872-8227 |
| Popis: | The understanding that statins reduce but not eliminate the cardiovascular risk associated with disturbed lipid metabolism and the existence of forms of dyslipidemia that are unresponsive or only partially responsive to statins have led to the development of many novel lipid-lowering drugs. Accumulating evidence suggests that the interplay between carbohydrate and lipid metabolism is bidirectional. Thus, any intervention that affects lipid metabolism has the potential to influence the homeostasis of glucose. In this review we summarize the available data on the effects of the evolving lipid-lowering drugs on carbohydrate metabolism. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect